东诚药业
(002675)
| 流通市值：110.62亿 | | | 总市值：122.70亿 |
| 流通股本：7.43亿 | | | 总股本：8.25亿 |
| 报告期 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 2,043,088,592.83 | 1,383,711,882.86 | 686,928,164.92 | 2,868,936,537.72 |
| 营业收入 | 2,043,088,592.83 | 1,383,711,882.86 | 686,928,164.92 | 2,868,936,537.72 |
| 二、营业总成本 | 1,862,700,437.32 | 1,268,737,113.89 | 637,737,923.53 | 2,649,051,861.74 |
| 营业成本 | 1,016,318,392.9 | 739,484,518.19 | 375,506,078 | 1,516,528,688.29 |
| 税金及附加 | 31,244,288.06 | 19,338,967.15 | 8,220,332.13 | 31,758,876.86 |
| 销售费用 | 323,232,350.7 | 206,446,290.18 | 96,489,290.28 | 414,767,086.97 |
| 管理费用 | 238,172,124.25 | 155,470,979.34 | 89,591,598.86 | 316,852,287.16 |
| 研发费用 | 162,333,434.08 | 94,745,266.76 | 44,008,471.83 | 291,911,236.55 |
| 财务费用 | 91,399,847.33 | 53,251,092.27 | 23,922,152.43 | 77,233,685.91 |
| 其中:利息费用 | 93,763,320.4 | 12,553,563.68 | 27,744,716.57 | 96,509,275.27 |
| 其中:利息收入 | 3,982,686.78 | 2,155,873.13 | 946,596.07 | 5,556,733.41 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 684,997.25 | 610,065.75 | 356,383.56 | 1,068,427.73 |
| 加:投资收益 | -10,265,375.8 | -6,374,584.07 | -1,617,047.95 | -13,984,963.44 |
| 资产处置收益 | 198,317.89 | 194,231.24 | 29,314.41 | 302,727.5 |
| 资产减值损失(新) | - | - | - | -83,874,940.6 |
| 信用减值损失(新) | -7,751,062.9 | -7,556,002.72 | -20,050,293.05 | -17,461,644.59 |
| 其他收益 | 19,193,543.08 | 11,766,564.02 | 7,381,975.47 | 114,871,715.14 |
| 四、营业利润 | 182,448,575.03 | 113,615,043.19 | 35,290,573.83 | 220,805,997.72 |
| 加:营业外收入 | 1,684,247.53 | 98,657.47 | 80,910.88 | 421,273.86 |
| 减:营业外支出 | 2,467,526.96 | 1,625,248.02 | 520,129.8 | 2,124,428.6 |
| 五、利润总额 | 181,665,295.6 | 112,088,452.64 | 34,851,354.91 | 219,102,842.98 |
| 减:所得税费用 | 57,110,205.82 | 42,049,138.94 | 17,701,550.31 | 77,677,833.3 |
| 六、净利润 | 124,555,089.78 | 70,039,313.7 | 17,149,804.6 | 141,425,009.68 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 124,555,089.78 | 70,039,313.7 | 17,149,804.6 | 141,425,009.68 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 149,115,907.27 | 88,652,457.27 | 24,731,523.19 | 183,825,711.34 |
| 少数股东损益 | -24,560,817.49 | -18,613,143.57 | -7,581,718.59 | -42,400,701.66 |
| 扣除非经常损益后的净利润 | 133,693,446.36 | 80,469,519.66 | 19,140,887.01 | 79,274,001.79 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.18 | 0.11 | 0.03 | 0.22 |
| (二)稀释每股收益 | 0.18 | 0.11 | 0.03 | 0.22 |
| 八、其他综合收益 | -1,998,026.56 | 1,813,407.68 | -2,717,138.25 | 9,642,842.77 |
| 归属于母公司股东的其他综合收益 | -4,315,783.19 | -327,958.84 | 125,100.49 | 7,985,818.5 |
| 九、综合收益总额 | 122,557,063.22 | 71,852,721.38 | 14,432,666.35 | 151,067,852.45 |
| 归属于母公司股东的综合收益总额 | 144,800,124.08 | 88,324,498.43 | 24,856,623.68 | 191,811,529.84 |
| 归属于少数股东的综合收益总额 | -22,243,060.86 | -16,471,777.05 | -10,423,957.33 | -40,743,677.39 |
| 公告日期 | 2025-10-29 | 2025-08-15 | 2025-04-30 | 2025-02-27 |
| 审计意见(境内) | | | | 标准无保留意见 |